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Summary. The binding sequence of the regulatory peptide
Neurotensin, NT(8-13), represents a promising tumour-
specific vector for the development of radiopeptides useful in
nuclear oncology for the diagnosis (imaging) and therapy of
cancer. A number of radiometal-labelled NT(8-13) derivatives
have been reported, however, the effect of the spacer which
connects the vector with the radiometal complex has yet not
been investigated systematically. Because a spacer moiety can
influence potentially important biological characteristics of
radiopeptides, we synthesized three [DOTA(177Lu)]-X-NT(8-
13) derivatives and evaluated the effect of a spacer (X) on
the physico-chemical properties of the conjugate including
lipophilicity, stability, and in vitro receptor affinity and cell
internalization.
1. Introduction
Regulatory peptides with high affinity towards cell mem-
brane receptors which are over-expressed by cancerous tis-
sues are promising vectors for the development of tumour-
specific radiotracers for the molecular imaging of cancer and
peptide receptor radionuclide therapy (PRRT) [1, 2]. Among
other peptides investigated, Neurotensin (NT), or its bind-
ing sequence NT(8-13) respectively, has been the subject
of radiotracer development for application in nuclear oncol-
ogy [3–6]. NT is a regulatory peptide present as a hormone
in the gastrointestinal tract [7] and as a neurotransmitter in
the central nervous system [8, 9]. The NT receptor (NTR)
family consists of the three subtypes, NTR1-3 [10], of which
NTR1 is of particular interest for radiotracer development
because of its over- expression in various tumours including
colon [11], lung [12], prostate [13], and breast cancer [14].
We are interested in the development of novel NT(8-13)-
based radiotracers with improved biological characteristics
(e.g., tumour uptake, in vivo stability, and fast clearance
from non-targeted tissue). At the onset of our work, we were
surprised to learn that no systematic evaluation of the ef-
fect of a spacer unit, which separates the tumour targeting
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vector (NT(8-13)) from the radioactive reporter probe (e.g.
a radiometal complex), has been reported. Because a spacer
unit can impact both the in vitro and in vivo properties of
such radioconjugates [15], we set out to investigate the ef-
fect of a spacer on NT(8-13)-derivatives functionalized N-
terminally with the universal macrocyclic chelator 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) for
the labeling with Lu-177. We chose two uncharged spac-
ers of different lipophilicity (aminohexanoic acid (Ahx) and
the tetraethyleneglycol (PEG4) motif), both of which have
been successfully used as a spacer moiety in radiometal pep-
tide conjugates [16, 17]. To assess the necessity of a spacer,
a derivative in which the DOTA and NT(8-13) units were
directly coupled was also included in the study. The three
radioconjugates were evaluated in vitro for a direct side-by-
side comparison of their physico-chemical properties.
2. Results and discussion
Three DOTA-X-NT(8-13) derivatives (X = spacer = PEG4,
Ahx, or no spacer) were synthesized by solid phase pep-
tide synthesis using standard Fmoc chemistry (Fig. 1). After
cleavage from the solid phase and deprotection, the pep-
tide conjugates were obtained in high purity and acceptable
yields after purification by preparative RP-HPLC (Table 1).
Identity of compounds 1–3 was confirmed by electrospray
mass spectroscopy.
NT-analogues 1-3 were radiolabelled with [177Lu]-LuCl3
in 0.4 M NH4OAc buffer at 100 ◦C for 30 min accord-
ing to literature procedures [18]. Analysis of the radio-
conjugates [177Lu(L)] (L = 1–3) by γ -HPLC indicated
an excellent radiochemical purity and yield of > 98%.
Achieved specific activity of the radiopeptides ranged from
2.3–10.8 MBq/nmol.
With radiopeptides [177Lu(L)] (L = 1–3) in hands, we
next investigated the effect of a spacer moiety on their
physico-chemical and in vitro properties. First, we exam-
ined the cell internalization behaviour of the novel com-
pounds in vitro with NTR1-expressing HT-29 cells (Fig. 2
and Table 2). Specificity of NTR1-mediated uptake was ver-
ified in each case by blocking experiments in the pres-
ence of 1000-fold excess NT(8-13). [177Lu(L)] (L = 1–3)
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Fig. 1. Structures of investigated NT(8-
13) derivatives: DOTA-PEG4-NT(8-
13) (1), DOTA-Ahx-NT(8-13) (2) and
DOTA-NT(8-13) (3).
Table 1. Analytical data of NT derivatives (1–3).
Compound Yield a Purity Calc. mass Mass observed
1 21% > 98% 1449.82 [M+H]+ = 1450.9
2 32% > 98% 1315.76 [M+H]+ = 1316.9
3 19% > 98% 1202.68 [M+H]+ = 1203.7
a: Yield after RP-HPLC purification.
showed specific cell internalization rates of approx. 3–7%
after 4 h of incubation, a rate comparable to data reported
for related radiometal labelled NT(8-13) derivatives [19]. Of
the compounds tested, those with a spacer moiety exhib-
ited a significant higher internalization rate than derivative
[177Lu(3)] without a spacer. Next, we performed receptor
binding saturation assays in order determine the affinity
(KD) of [177Lu(L)] (L = 1–3) towards the NTR1 receptor
(Fig. 2 and Table 2). Again, receptor specificity was verified
by blocking experiments. All derivatives [177Lu(L)] (L =
1–3) showed a high and specific affinity towards the NTR1
receptor with KD values in the single-to-two-digit nanomo-
lar range, a value typically observed for NT-based radiotrac-
ers [5]. In general, derivatives with a spacer ([177Lu(L)] (L =
1, 2)) exhibited a more favourable KD than [177Lu(3)] which
lacks such a moiety. Thus, the data obtained from the in vitro
evaluation of the compounds suggests that the presence of
a spacer moiety in radiometal-based NT(8-13) conjugates
can be advantageous.
It is known that the spacer unit of a radiometal-labelled
peptide can alter the lipophilicity of the conjugate, which
in turn can impact its pharmacokinetic and -dynamic pro-
file (e.g., rate and route of excretion) [4, 20]. We there-
fore determined the partition coefficient (logD) of [177Lu(L)]
(L = 1–3) in n-octanol/PBS by the shake flask method
for a qualitative comparison of the compounds’ lipophilic-
ities (n = 3 in quintuples; Table 2). To our surprise, nei-
ther the presence of a spacer nor its chemical composition
appeared to influence significantly the log D of the conju-
gates. It is therefore likely that either the amino acid se-
quence of NT(8-13) and/or the 177Lu-DOTA chelate deter-
mine the lipophilic character of the conjugates. Regardless,
compound [177Lu(1)] with a PEG4 spacer exhibited the high-
est hydrophilicity, a characteristic which could be consid-
ered as an indicator for a potential favourable fast renal
excretion of the radiotracer in vivo [17, 20].
Another important property of radiolabelled regulatory
peptides is their instability towards intra- and extracellular
proteases. Rapid degradation in vivo often results in a bi-
ological half-life of only a few minutes [21]. It has been
shown that an increased stability of radiolabelled peptides
correlates with an enhanced accumulation of radioactivity in
targeted tissue, an important parameter for both diagnostic
and therapeutic applications [22]. Even though the focus of
the work presented herein does not lie on the stabilization
of the peptidic vector, we investigated the effect of a spacer
on the stability of the NT(8-13) derivatives (Table 2). Thus,
[177Lu(L)] (L = 1–3) were incubated in blood serum for
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Fig. 2. In vitro evaluation of [177Lu(L)] (L = 1–3) with NTR1 ex-
pressing HT-29 cell. (a) Specific cell internalization and (b) receptor
binding saturation experiments. Data is presented as mean ± standard
deviation (n = 3 in triplicates) and fitted by non-linear regression with
GraphPad Prism 5.0.
Table 2. Summary of the physico-chemical properties of [177Lu(L)] (L
= 1–3).
Compound % internalization a KD [nM] log P T b1/2
[177Lu(1)] 7.3±0.4 3.8±0.9 −2.6 < 5 min
[177Lu(2)] 5.6±0.4 3.4±1.5 −2.3 < 5 min
[177Lu(3)] 3.0±0.2 14.9±0.7 −2.5 < 5 min
a: Specific cell internalization after 4 h of incubation;
b: Half-life (T1/2) in blood serum.
up to 2 h at 37 ◦C and samples were taken at different time
points. After precipitation of proteins, the supernatant was
analyzed by γ -HPLC for determination of the ratio of in-
tact radiopeptide versus proteolytic degradation products.
Not surprisingly, all compounds exhibited a short half-life
(T1/2) of approx. < 5 min. Similar half-lifes have been re-
ported for non-stabilized derivatives of the native binding
sequence of Neurotensin [5]. The experimental data indi-
cate, that a spacer unit does not seem to have a significant
effect on the stability of the NT(8-13) conjugates in blood
serum.
3. Conclusions
In summary, we report the synthesis, radiolabelling and
in vitro evaluation of three 177Lu-labelled DOTA-NT(8-13)
derivatives in order to assess the effect of a spacer moiety
on their physico-chemical properties. We were able to show
that a spacer moiety between the targeting peptide NT(8-13)
and the radiometal chelate [177Lu(DOTA)] is beneficial with
regards to receptor affinity and cell internalization proper-
ties of the conjugate in vitro. On the other hand, the presence
of a spacer and/or its chemical composition had little in-
fluence on the lipophilicity and blood serum stability of the
radiopeptide. For our on-going work on the development of
novel NT-based radiotracers, we will account for these data
and include a spacer as a structural element of the conjugate.
4. Experimental procedures
4.1 General procedures
HOBt, HATU AND TBTU were purchased from Merck
Biosciences (Nottingham, UK). The preloaded resin Fmoc-
L-Leu-PEG-PS was purchased from Applied Biosystems
(Warrington, UK). Fmoc-PEG4-OH was purchased from
PolyPeptide Group (Strasbourg, France). Fmoc-amino acids
and Neurotensin (8-13) was purchased from Bachem (Bu-
bendorf, Switzerland). DOTA(tBu)3,was purchased from
Chematech (Dijon, France). Solvents and other chemicals
were purchased from Acros Organics (Geel, Belgium),
Merck (Darmstadt, Germany) or Sigma-Aldrich (Buchs,
Switzerland). Automated solid-phase synthesis was per-
formed on a Pioneer synthesizer (Applied Biosystems).
Polypropylene syringes for manual peptide couplings, fitted
with polypropylene frits and plungers were obtained with
MultiSynthech (Witten, Germany). 177LuCl3 in 0.05 M HCl
was purchased either from IDB (Baarle-Nassau, Nether-
lands), ITG (München, Germany) or Perkin Elmer (Boston,
USA). Analytical and preparative HPLC were carried out
with systems from Bischoff Chromatography, equipped
with a λ-1010 UV/Vis and an LB509 radioflow detector
(Berthold Technologies), using C18 reversed-phase columns
(Macherey Nagel Nucleodur C18 ISIS, 5μm (Column A),
250 x 4.6 mm for analytics and Macherey Nagel Nucleodur
C18 ISIS, 5μm, 250 × 16.0 mm (Column B) for purifi-
cations). HPLC solvents were 0.1% TFA in H2O (A) and
MeCN (B); flow: 1.5 mL/min. For analytics a linear gradi-
ent from 85% to 50% A in 20 min was used. Quality control
of the radiometal labelled peptides was performed using
Column A and a linear gradient using 90% to 50% A in
15 min; flow: 1.5 mL/min. Removal of MeCN from prepar-
ative HPLC fractions was performed with a Jouan RC1022
centrifugal evaporator equipped with a Jouan RC90 cooling
trap. Lyophilization of the peptides was performed on an Al-
pha 1-2 LD plus lyophilizer (Christ). LRMS analyses were
performed on a ESI Bruker Esquire 3000 plus. Quantita-
tive γ -counting was performed on a COBRA II auto-gamma
system (Model 5003, Packard Instruments).
4.2 Solid phase synthesis
The amino acid sequence of Neurotensin (8-13) was syn-
thesized on solid support (Fmoc-L-Leu-PEG-PS resin;
0.03 mmol) using standard Fmoc chemistry on an automated
peptide synthesizer. TBTU-HOBt was used as a coupling
reagent and 20% piperidine in DMF as the deprotection
reagent. Automated syntheses were carried out with a 4-fold
excess of protected amino acids and coupling reagents. For
the manual solid phase syntheses, 3-fold excess of protected
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coupling moiety (spacer and chelator, respectively) in pres-
ence of HATU (3.0 eq) and DIPEA (5.0 eq) were used. The
couplings were performed in DMF with a standard reac-
tion time of 2 h. Completion of the reaction was confirmed
by Kaiser test. Elongation yields were obtained by meas-
uring the UV-absorption of the fluorenylmethylpiperidine
adduct after Fmoc-deprotection in 20% piperidine in DMF
(3×2 min). The peptides were deprotected and cleaved from
the resin at rt for 4 h using a solution of 95% TFA, 2.5% H2O
and 2.5% trisisopropylsilane as a cleavage cocktail. After re-
moval of the TFA by evaporation and precipitation in cold
diethyl ether, the crude peptide obtained was washed three
times with cold diethyl ether and purified by preparative RP-
HPLC. After purification, the peptides were lyophilized and
characterized by ESI-MS and analytical RP-HPLC.
4.3 Radiolabelling of the peptides
For the labelling of the peptides 1–3 with 177Lu, stock so-
lutions of 1 mg/mL of the peptides conjugates 1–3 in wa-
ter were prepared. For each labelling, 10–20μg (10–20 μL
stock solution) were added to 150–300μL of 0.4 M ammo-
nium acetate (pH 5.4). 37–122 MBq of a stock solution of
177LuCl3 in H2O was added and the mixture was incubated
for 30 min at 100 ◦C. Afterwards, the radiolabelled peptides
were incubated with approx. 3×10−4 M cold LuCl3 (0.8 eq.)
for 30 min at 100 ◦C. Quality control was performed by γ -
HPLC analysis of a 2μL aliquot of the solution in 30 μL
of 0.1 M Ca-EDTA. For the experiments described in the
following, the labelling solutions were further diluted with
a 0.9% NaCl to a concentration of 10−6 M. This solution
was used a stock solution for the binding saturation experi-
ments. For internalization experiments, a second dilution
to a concentration of 2.5×10−8 M (2.5 pmol/100μL) was
performed.
4.4 Stability studies
The radiolabelled peptides [177Lu(L)] (L = 1–3) (30 pmol,
1 nM in PBS, pH 5.4) were incubated at 37 ◦C with 1 mL
fresh blood serum. At different time points (0, 5, 10, 15, 20,
30, 40, 50, 60, 120, 240 min) aliquots were taken, proteins
were precipitated by addition of 200μL EtOH, centrifuga-
tion for 10 min at 5000 rpm and the supernatant was ana-
lysed by γ -HPLC (n = 3).
4.5 log D determination
The lipophilicity of [177Lu(L)] (L = 1–3) was determined by
the ‘shake flask method’ measuring the partition coefficient
of the radiolabelled peptides in n-octanol/PBS. The radi-
olabelled peptides (30 pmol, 1 nM in PBS; 300–325 kBq)
were added to 1 mL of a mixture of n-octanol/PBS (50%
v/v). The mixture was then mixed thoroughly for 1 min by
vortex. Both layers were separated by centrifugation (5 min;
1500 rpm) and analysed with a gamma-counter (n = 5).
4.6 In vitro experiments
Cell culturing
Human colorectal adenocarcinoma (HT-29) cells were ob-
tained from American Type Culture Collection (ATCC,
Manassas, USA) and cultured at 37 ◦C and 5% CO2 in Dul-
becco’s modified Eagle’s medium (DMEM, high glucose)
containing 10% (v/v) fetal bovine serum (FBS Superior,
OXOID, Pratteln, Switzerland), L-glutamine (200 mM), 100
IU mL−1 penicillin and 100 μg mL−1 streptomycin. All the
culture reagents, except FBS, were purchased at Biocon-
cept (Allschwil, Switzerland). The cells were subcultured
weekly after detaching them with a commercial solution of
trypsin-EDTA (1 : 250) in PBS.
Internalization studies
On the day prior to the experiment, HT-29 cells (106 cells
per well) were placed in six-well plates with cell culture
medium (1% FBS) and incubated overnight at 37 ◦C and 5%
CO2 for allowing the cells to attach. On the day of the ex-
periment, the medium was removed and incubated in fresh
medium (1% FBS, 1.3 mL) for 1 h at 37 ◦C and 5% CO2. Ra-
diolabelled conjugates [177Lu(L)] (L = 1–3) (2.5 pmol per
well, 2.5 pM solution in PBS) were added and the cells were
incubated for different time points (30, 60, 120, 240 min)
in triplicates to allow binding and internalization. Non-
specific receptor binding and internalization was determined
by blocking experiments in the presence of a 1000-fold ex-
cess of NT(8-13) as a blocking agent (2.5 nmol per well,
2.5 nM solution in H2O). After each time point, the super-
natant was removed and the cells were washed twice with
PBS (1 mL). The combined supernatants represent the free,
unbound fraction of radioactivity. Receptor-bound radioac-
tivity was determined by incubating the cells on ice twice for
5 min with an acidic glycine solution (1 mL; 100 nM NaCl,
50 nM glycine, pH 2.8). The internalized fraction was iso-
lated by lysis of the cells with 1 M NaOH (1 mL) for 10 min
at 37 ◦C and 5% CO2. The wells of the lysed cells were
washed twice with 1 mL NaOH. The radioactivity of the
fractions were measured quantitatively in a gamma counter
and calculated as a percentage of applied dose. Data was fit-
ted by non-linear regression with GraphPad Prism 5.0 (n = 3
in triplicate).
Binding saturation studies
HT 29 cells in six-well plates were prepared as described
above. In order to reach receptor saturation, the cells were
incubated with increasing concentrations of the peptide con-
jugates [177Lu(L)] (L = 1–3; 0.1, 0.5, 1, 5, 10, 20, 50,
75, 100, 200 nM). Non-specific binding was determined by
blocking experiments using excess Neurotensin (8-13) so-
lution (2.5 nmol/1 mL per well, corresponding to 2.5μM).
After incubation of 1 h at 37 ◦C and 5% CO2, the super-
natant was removed and the cells were washed twice with
PBS (1 mL per well). The combined supernatants represent
the free, unbound radiopeptide fraction. In order to deter-
mine the receptor bound and internalized fraction, the cells
were lysed with 1 M NaOH (1 mL per well) for 10 min at
37 ◦C and washed twice with 1 M NaOH (1 mL per well).
The free and the receptor bound fractions were measured
in a gamma counter for quantification. Dissociation con-
stants (KD) were calculated from the specific binding data by
performing a non-linear regression using GraphPad Prism5
(n = 3 in triplicate).
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